 | Up a level |
2022
Huber, Henriette, Edenhofer, Simone, von Tresckow, Julia, Robrecht, Sandra, Zhang, Can, Tausch, Eugen, Schneider, Christof, Bloehdorn, Johannes 
ORCID: 0000-0003-1433-9702, Fuerstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna L., Duerig, Jan, Boettcher, Sebastian, Niemann, Carsten U., Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Doehner, Hartmut, Hallek, Michael ORCID: 0000-0002-7425-4455, Eichhorst, Barbara and Stilgenbauer, Stephan
(2022).
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood, 139 (9).
S. 1318 - 1330.
WASHINGTON:
AMER SOC HEMATOLOGY.
ISSN 1528-0020
Huber, Henriette, Tausch, Eugen, Schneider, Christof, Edenhofer, Simone, Von Tresckow, Julia, Robrecht, Sandra, Giza, Adam, Zhang, Can, Furstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna Lena, Duerig, Jan, Boettcher, Sebastian, Niemann, Carsten Utoft, Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Doehner, Hartmut, Hallek, Michael, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
2014
Stilgenbauer, Stephan, Cymbalista, Florence, Leblond, Veronique, Delmer, Alain, Ibach, Stefan, Choquet, Sylvain, Dartigeas, Caroline, Cazin, Bruno, Tournilhac, Olivier, Pegourie, Brigitte, Seiler, Till M., Soekler, Martin, Zirlik, Katja, Alt, Juergen, Huber, Henriette, Bloehdorn, Johannes, Tausch, Eugen, Zenz, Thorsten, Hallek, Michael, Schetelig, Johannes, Dreger, Peter and Doehner, Hartmut (2014). Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in ultra High-risk CLL: Final Results from the CLL2O Phase II Study. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020